Mass balance in rapamycin autoxidation
The immunosuppressant drug rapamycin is a complex polyene-containing natural product which undergoes autoxidation. The resulting product mixtures contained numerous monomeric and oligomeric compounds, which represented challenges for addressing mass balance in forced degradation studies and in analy...
Gespeichert in:
| Veröffentlicht in: | Journal of pharmaceutical and biomedical analysis 2008-12, Vol.48 (5), p.1368-1374 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1374 |
|---|---|
| container_issue | 5 |
| container_start_page | 1368 |
| container_title | Journal of pharmaceutical and biomedical analysis |
| container_volume | 48 |
| creator | Oyler, Alan R. Armstrong, Barbara L. Dunphy, Richard Alquier, Lori Maryanoff, Cynthia A. Cohen, Judith H. Merciadez, Mel Khublall, Ada Mehta, Rajshekhar Patel, Ashesh Il’ichev, Yuri V. |
| description | The immunosuppressant drug rapamycin is a complex polyene-containing natural product which undergoes autoxidation. The resulting product mixtures contained numerous monomeric and oligomeric compounds, which represented challenges for addressing mass balance in forced degradation studies and in analysis of aged developmental drug-eluting stents. A combination of SEC with ultraviolet and refractive index detection and RP-HPLC was used to account for drug loss and product formation. The mass balance methodology was subsequently validated for the determination of rapamycin and composite rapamycin autoxidation product material in developmental stent samples. This mass balance approach may find general applicability in other situations where drugs degrade to a plethora of products, which cannot be determined individually and summed. |
| doi_str_mv | 10.1016/j.jpba.2008.09.030 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_66652127</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708508005189</els_id><sourcerecordid>66652127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-4251e8850e921b15827e158e31c6dd8105da3ccbac70eb065dbe31ff2731d3e53</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlb_gAfpxd52ncludrPgRYpfUPGi4C1kk1lIabs12RX7703pojcvk4E8M_PyMHaJkCJgcbNMl9tapxxAplClkMERG6Mss4QX-ccxG0OZYVKCFCN2FsISAARW-SkbYQVYFcjHbPaiQ5jWeqU3hqZuM_V6q9c7Ezvdd-23s7pz7eacnTR6FehieCfs_eH-bf6ULF4fn-d3i8RkMu-SnAskKQVQxbFGIXlJsVKGprBWIgirM2NqbUqgGgph6_jXNDwGtRmJbMJmh71b3372FDq1dsHQKsajtg-qKArBMeITxg-g8W0Inhq19W6t_U4hqL0dtVR7O2pvR0Glop04dDVs7-s12b-RQUcErgdAB6NXjY9WXPjl4mWUUO5j3h44ii6-HHkVjKNo0DpPplO2df_l-AG_xIFL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66652127</pqid></control><display><type>article</type><title>Mass balance in rapamycin autoxidation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Oyler, Alan R. ; Armstrong, Barbara L. ; Dunphy, Richard ; Alquier, Lori ; Maryanoff, Cynthia A. ; Cohen, Judith H. ; Merciadez, Mel ; Khublall, Ada ; Mehta, Rajshekhar ; Patel, Ashesh ; Il’ichev, Yuri V.</creator><creatorcontrib>Oyler, Alan R. ; Armstrong, Barbara L. ; Dunphy, Richard ; Alquier, Lori ; Maryanoff, Cynthia A. ; Cohen, Judith H. ; Merciadez, Mel ; Khublall, Ada ; Mehta, Rajshekhar ; Patel, Ashesh ; Il’ichev, Yuri V.</creatorcontrib><description>The immunosuppressant drug rapamycin is a complex polyene-containing natural product which undergoes autoxidation. The resulting product mixtures contained numerous monomeric and oligomeric compounds, which represented challenges for addressing mass balance in forced degradation studies and in analysis of aged developmental drug-eluting stents. A combination of SEC with ultraviolet and refractive index detection and RP-HPLC was used to account for drug loss and product formation. The mass balance methodology was subsequently validated for the determination of rapamycin and composite rapamycin autoxidation product material in developmental stent samples. This mass balance approach may find general applicability in other situations where drugs degrade to a plethora of products, which cannot be determined individually and summed.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2008.09.030</identifier><identifier>PMID: 19019612</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Analytical, structural and metabolic biochemistry ; Autoxidation ; Biological and medical sciences ; Chromatography, High Pressure Liquid - instrumentation ; Chromatography, High Pressure Liquid - methods ; Dimerization ; Drug-Eluting Stents ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Immunosuppressive Agents - analysis ; Immunosuppressive Agents - chemistry ; Mass balance ; Medical sciences ; Molecular Structure ; Oxidation-Reduction ; Pharmacology. Drug treatments ; Rapamycin ; Refractometry - methods ; RP-HPLC ; SEC ; Sirolimus - analysis ; Sirolimus - chemistry ; Spectrophotometry, Ultraviolet - methods</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2008-12, Vol.48 (5), p.1368-1374</ispartof><rights>2008 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-4251e8850e921b15827e158e31c6dd8105da3ccbac70eb065dbe31ff2731d3e53</citedby><cites>FETCH-LOGICAL-c384t-4251e8850e921b15827e158e31c6dd8105da3ccbac70eb065dbe31ff2731d3e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jpba.2008.09.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21218075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19019612$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oyler, Alan R.</creatorcontrib><creatorcontrib>Armstrong, Barbara L.</creatorcontrib><creatorcontrib>Dunphy, Richard</creatorcontrib><creatorcontrib>Alquier, Lori</creatorcontrib><creatorcontrib>Maryanoff, Cynthia A.</creatorcontrib><creatorcontrib>Cohen, Judith H.</creatorcontrib><creatorcontrib>Merciadez, Mel</creatorcontrib><creatorcontrib>Khublall, Ada</creatorcontrib><creatorcontrib>Mehta, Rajshekhar</creatorcontrib><creatorcontrib>Patel, Ashesh</creatorcontrib><creatorcontrib>Il’ichev, Yuri V.</creatorcontrib><title>Mass balance in rapamycin autoxidation</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>The immunosuppressant drug rapamycin is a complex polyene-containing natural product which undergoes autoxidation. The resulting product mixtures contained numerous monomeric and oligomeric compounds, which represented challenges for addressing mass balance in forced degradation studies and in analysis of aged developmental drug-eluting stents. A combination of SEC with ultraviolet and refractive index detection and RP-HPLC was used to account for drug loss and product formation. The mass balance methodology was subsequently validated for the determination of rapamycin and composite rapamycin autoxidation product material in developmental stent samples. This mass balance approach may find general applicability in other situations where drugs degrade to a plethora of products, which cannot be determined individually and summed.</description><subject>Analysis</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Autoxidation</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid - instrumentation</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Dimerization</subject><subject>Drug-Eluting Stents</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>Immunosuppressive Agents - analysis</subject><subject>Immunosuppressive Agents - chemistry</subject><subject>Mass balance</subject><subject>Medical sciences</subject><subject>Molecular Structure</subject><subject>Oxidation-Reduction</subject><subject>Pharmacology. Drug treatments</subject><subject>Rapamycin</subject><subject>Refractometry - methods</subject><subject>RP-HPLC</subject><subject>SEC</subject><subject>Sirolimus - analysis</subject><subject>Sirolimus - chemistry</subject><subject>Spectrophotometry, Ultraviolet - methods</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotlb_gAfpxd52ncludrPgRYpfUPGi4C1kk1lIabs12RX7703pojcvk4E8M_PyMHaJkCJgcbNMl9tapxxAplClkMERG6Mss4QX-ccxG0OZYVKCFCN2FsISAARW-SkbYQVYFcjHbPaiQ5jWeqU3hqZuM_V6q9c7Ezvdd-23s7pz7eacnTR6FehieCfs_eH-bf6ULF4fn-d3i8RkMu-SnAskKQVQxbFGIXlJsVKGprBWIgirM2NqbUqgGgph6_jXNDwGtRmJbMJmh71b3372FDq1dsHQKsajtg-qKArBMeITxg-g8W0Inhq19W6t_U4hqL0dtVR7O2pvR0Glop04dDVs7-s12b-RQUcErgdAB6NXjY9WXPjl4mWUUO5j3h44ii6-HHkVjKNo0DpPplO2df_l-AG_xIFL</recordid><startdate>20081215</startdate><enddate>20081215</enddate><creator>Oyler, Alan R.</creator><creator>Armstrong, Barbara L.</creator><creator>Dunphy, Richard</creator><creator>Alquier, Lori</creator><creator>Maryanoff, Cynthia A.</creator><creator>Cohen, Judith H.</creator><creator>Merciadez, Mel</creator><creator>Khublall, Ada</creator><creator>Mehta, Rajshekhar</creator><creator>Patel, Ashesh</creator><creator>Il’ichev, Yuri V.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20081215</creationdate><title>Mass balance in rapamycin autoxidation</title><author>Oyler, Alan R. ; Armstrong, Barbara L. ; Dunphy, Richard ; Alquier, Lori ; Maryanoff, Cynthia A. ; Cohen, Judith H. ; Merciadez, Mel ; Khublall, Ada ; Mehta, Rajshekhar ; Patel, Ashesh ; Il’ichev, Yuri V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-4251e8850e921b15827e158e31c6dd8105da3ccbac70eb065dbe31ff2731d3e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Analysis</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Autoxidation</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid - instrumentation</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Dimerization</topic><topic>Drug-Eluting Stents</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>Immunosuppressive Agents - analysis</topic><topic>Immunosuppressive Agents - chemistry</topic><topic>Mass balance</topic><topic>Medical sciences</topic><topic>Molecular Structure</topic><topic>Oxidation-Reduction</topic><topic>Pharmacology. Drug treatments</topic><topic>Rapamycin</topic><topic>Refractometry - methods</topic><topic>RP-HPLC</topic><topic>SEC</topic><topic>Sirolimus - analysis</topic><topic>Sirolimus - chemistry</topic><topic>Spectrophotometry, Ultraviolet - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oyler, Alan R.</creatorcontrib><creatorcontrib>Armstrong, Barbara L.</creatorcontrib><creatorcontrib>Dunphy, Richard</creatorcontrib><creatorcontrib>Alquier, Lori</creatorcontrib><creatorcontrib>Maryanoff, Cynthia A.</creatorcontrib><creatorcontrib>Cohen, Judith H.</creatorcontrib><creatorcontrib>Merciadez, Mel</creatorcontrib><creatorcontrib>Khublall, Ada</creatorcontrib><creatorcontrib>Mehta, Rajshekhar</creatorcontrib><creatorcontrib>Patel, Ashesh</creatorcontrib><creatorcontrib>Il’ichev, Yuri V.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oyler, Alan R.</au><au>Armstrong, Barbara L.</au><au>Dunphy, Richard</au><au>Alquier, Lori</au><au>Maryanoff, Cynthia A.</au><au>Cohen, Judith H.</au><au>Merciadez, Mel</au><au>Khublall, Ada</au><au>Mehta, Rajshekhar</au><au>Patel, Ashesh</au><au>Il’ichev, Yuri V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mass balance in rapamycin autoxidation</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2008-12-15</date><risdate>2008</risdate><volume>48</volume><issue>5</issue><spage>1368</spage><epage>1374</epage><pages>1368-1374</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>The immunosuppressant drug rapamycin is a complex polyene-containing natural product which undergoes autoxidation. The resulting product mixtures contained numerous monomeric and oligomeric compounds, which represented challenges for addressing mass balance in forced degradation studies and in analysis of aged developmental drug-eluting stents. A combination of SEC with ultraviolet and refractive index detection and RP-HPLC was used to account for drug loss and product formation. The mass balance methodology was subsequently validated for the determination of rapamycin and composite rapamycin autoxidation product material in developmental stent samples. This mass balance approach may find general applicability in other situations where drugs degrade to a plethora of products, which cannot be determined individually and summed.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19019612</pmid><doi>10.1016/j.jpba.2008.09.030</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0731-7085 |
| ispartof | Journal of pharmaceutical and biomedical analysis, 2008-12, Vol.48 (5), p.1368-1374 |
| issn | 0731-7085 1873-264X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66652127 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Analysis Analytical, structural and metabolic biochemistry Autoxidation Biological and medical sciences Chromatography, High Pressure Liquid - instrumentation Chromatography, High Pressure Liquid - methods Dimerization Drug-Eluting Stents Fundamental and applied biological sciences. Psychology General pharmacology Immunosuppressive Agents - analysis Immunosuppressive Agents - chemistry Mass balance Medical sciences Molecular Structure Oxidation-Reduction Pharmacology. Drug treatments Rapamycin Refractometry - methods RP-HPLC SEC Sirolimus - analysis Sirolimus - chemistry Spectrophotometry, Ultraviolet - methods |
| title | Mass balance in rapamycin autoxidation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T19%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mass%20balance%20in%20rapamycin%20autoxidation&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Oyler,%20Alan%20R.&rft.date=2008-12-15&rft.volume=48&rft.issue=5&rft.spage=1368&rft.epage=1374&rft.pages=1368-1374&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/j.jpba.2008.09.030&rft_dat=%3Cproquest_cross%3E66652127%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66652127&rft_id=info:pmid/19019612&rft_els_id=S0731708508005189&rfr_iscdi=true |